Haleon's (HLN) "Hold (C)" Rating Reiterated at Weiss Ratings

Key Points

• Haleon's stock rating was reiterated at a "hold (c)" by Weiss Ratings, while other analysts have provided mixed ratings, with Goldman Sachs upgrading it to "buy".
• The current average rating for Haleon is "Moderate Buy" with a consensus target price of $12.33.
• Haleon's shares experienced a 2.6% increase, with trading prices opening at $9.05, amidst various institutional investors increasing their stakes in the company.

Haleon (NYSE:HLN - Get Free Report)'s stock had its "hold (c)" rating reissued by equities researchers at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

Other analysts have also issued reports about the stock. The Goldman Sachs Group upgraded shares of Haleon from a "neutral" rating to a "buy" rating in a research report on Wednesday, September 10th. Wall Street Zen lowered shares of Haleon from a "buy" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, Barclays lowered shares of Haleon from an "overweight" rating to an "equal weight" rating in a research report on Tuesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Haleon has an average rating of "Moderate Buy" and a consensus target price of $12.33.

Haleon Trading Up 2.6%

Shares of HLN opened at $9.05 on Wednesday. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. The firm's 50-day moving average is $9.45 and its two-hundred day moving average is $10.04. Haleon has a twelve month low of $8.71 and a twelve month high of $11.42. The firm has a market capitalization of $40.32 billion, a P/E ratio of 23.21, a PEG ratio of 2.61 and a beta of 0.20.

Hedge Funds Weigh In On Haleon

Several institutional investors and hedge funds have recently modified their holdings of the company. Private Trust Co. NA lifted its stake in shares of Haleon by 13.3% during the second quarter. Private Trust Co. NA now owns 8,794 shares of the company's stock valued at $91,000 after buying an additional 1,032 shares during the period. Farther Finance Advisors LLC raised its stake in Haleon by 8.8% during the first quarter. Farther Finance Advisors LLC now owns 12,861 shares of the company's stock worth $131,000 after purchasing an additional 1,041 shares during the period. Apollon Wealth Management LLC raised its stake in Haleon by 5.4% during the first quarter. Apollon Wealth Management LLC now owns 21,722 shares of the company's stock worth $224,000 after purchasing an additional 1,111 shares during the period. Cary Street Partners Financial LLC raised its stake in Haleon by 20.1% during the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company's stock worth $69,000 after purchasing an additional 1,113 shares during the period. Finally, Simplicity Wealth LLC raised its stake in Haleon by 7.9% during the first quarter. Simplicity Wealth LLC now owns 15,482 shares of the company's stock worth $159,000 after purchasing an additional 1,135 shares during the period. Hedge funds and other institutional investors own 6.67% of the company's stock.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.